Interferon-alpha treatment of patients with Hepatitis C: the role of a comprehensive risk-benefit assessment.
Rifai
Muhamad Aly
MA
Loftis
Jennifer M
JM
Hauser
Peter
P
D000998:Antiviral Agents / Q000627:therapeutic use*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D011994:Recombinant Proteins; D018570:Risk Assessment
D000998:Antiviral Agents; D007370:Interferon Type I; D011994:Recombinant Proteins